A Randomized Controlled Trial of Ivermectin Monotherapy versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in COVID- 19 Patients in Nigeria
O E Babalola, YA Ndanusa, AA Ajayi, JO Ogedengbe, Y Thairu, O Omede
Abstract
2-way Repeated measures Analysis of Variance (RMANOVA) did not show any difference between the two groups. However, there was a significant time effect (improvement over time) for SpO<sub>2</sub>, Ct N-gene, Ct E-gene and clinical status in both groups, and significant reductions in inflammatory markers by day 7 (P < 0.0001).
Topics & Concepts
AzithromycinIvermectinHydroxychloroquineMedicineCoronavirus disease 2019 (COVID-19)Analysis of varianceRandomized controlled trialInternal medicineSignificant differenceVeterinary medicineBiologyAntibioticsGeneticsInfectious disease (medical specialty)DiseaseParasitic Diseases Research and TreatmentParasites and Host InteractionsAutism Spectrum Disorder Research